19 June 2013
Keywords: pathogenesis, begins, ph, ii, rifalazil, trial, begun
Article | 23 October 1997
- PathoGenesis has begun a Phase II trial of rifalazil (PA-1648), aderivative of rifampin, the standard therapy for the treatment of
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
© 2013 thepharmaletter.com